Reversal of tacrolimus-related hypertrophic cardiomyopathy after conversion to rapamycin in a pediatric liver transplant recipient.
Tacrolimus (Tac)-related hypertrophic cardiomyopathy (HCM) has been reported to be an unusual but serious complication affecting pediatric patients after solid organ transplantation. Herein, we present a case of young liver transplant recipient with Tac-induced HCM, treated by discontinuation of Tac followed by conversion to rapamycin (Rap). Our case report points out the potential but rather low risk of HCM during Tac immunosuppression in pediatric liver transplants and demonstrates that replacement of calcineurin inhibitors with mammalian target of Rap (mTOR) inhibitors may be an efficacious therapeutic tool to effect regression of established cardiac hypertrophy.
Turska-Kmieć
Anna
A
Department of Cardiology, The Children's Memorial Health Institute, Warsaw, Poland. turskakmiec@op.pl
Jankowska
Irena
I
Pawłowska
Joanna
J
Kaliciński
Piotr
P
Kawalec
Wanda
W
Tomyn
Małgorzata
M
Markiewicz
Małgorzata
M
Teisseyre
Joanna
J
Czubkowski
Piotr
P
Rekawek
Joanna
J
Socha
Jerzy
J
D002312:Cardiomyopathy, Hypertrophic / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000188:drug therapy; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D007223:Infant; D016031:Liver Transplantation; D020123:Sirolimus / Q000627:therapeutic use*; D016559:Tacrolimus / Q000009:adverse effects*; D014463:Ultrasonography
D007166:Immunosuppressive Agents; D020123:Sirolimus; D016559:Tacrolimus